Michael A Moso1,2,3, Jenny L Anderson1, Samantha Adikari1, Lachlan R Gray2,3, Georges Khoury1,4, Judy J Chang1, Jonathan C Jacobson1,4, Anne M Ellett3, Wan-Jung Cheng3, Suha Saleh1, John J Zaunders5,6, Damian F J Purcell1,4, Paul U Cameron1,2,3, Melissa J Churchill7, Sharon R Lewin1,2, Hao K Lu1. 1. The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital. 2. Department of Infectious Diseases, Alfred Hospital and Monash University. 3. Centre for Biomedical Research, Burnet Institute. 4. Department of Microbiology and Immunology at The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria. 5. Kirby Institute, University of New South Wales. 6. Centre for Applied Medical Research, St. Vincent's Hospital, Sydney, New South Wales. 7. School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Abstract
OBJECTIVE: To determine whether latency can be established and reversed in both proliferating and nonproliferating CD4+ T cells in the same model in vitro. METHODS: Activated CD4+ T cells were infected with either a nonreplication competent, luciferase reporter virus or wild-type full-length enhanced green fluorescent protein (EGFP) reporter virus and cultured for 12 days. The cells were then sorted by flow cytometry to obtain two distinct T-cell populations that did not express the T-cell activation markers, CD69, CD25 and human leukocyte antigen (HLA)-DR: CD69CD25HLA-DR small cells (nonblasts) that had not proliferated in vitro following mitogen stimulation and CD69CD25HLA-DR large cells (which we here call transitional blasts) that had proliferated. The cells were then reactivated with latency-reversing agents and either luciferase or EGFP quantified. RESULTS: Inducible luciferase expression, consistent with latent infection, was observed in nonblasts and transitional blasts following stimulation with either phorbol-myristate-acetate/phytohemagglutinin (3.8 ± 1 and 2.9 ± 0.5 fold above dimethyl sulfoxide, respectively) or romidepsin (2.1 ± 0.6 and 1.8 ± 0.2 fold above dimethyl sulfoxide, respectively). Constitutive expression of luciferase was higher in transitional blasts compared with nonblasts. Using wild-type full-length EGFP reporter virus, inducible virus was observed in nonblasts but not in transitional blasts. No significant difference was observed in the response to latency-reversing agents in either nonblasts or transitional blasts. CONCLUSION: HIV latency can be established in vitro in resting T cells that have not proliferated (nonblasts) and blasts that have proliferated (transitional blasts). This model could potentially be used to assess new strategies to eliminate latency.
OBJECTIVE: To determine whether latency can be established and reversed in both proliferating and nonproliferating CD4+ T cells in the same model in vitro. METHODS: Activated CD4+ T cells were infected with either a nonreplication competent, luciferase reporter virus or wild-type full-length enhanced green fluorescent protein (EGFP) reporter virus and cultured for 12 days. The cells were then sorted by flow cytometry to obtain two distinct T-cell populations that did not express the T-cell activation markers, CD69, CD25 and human leukocyte antigen (HLA)-DR: CD69CD25HLA-DR small cells (nonblasts) that had not proliferated in vitro following mitogen stimulation and CD69CD25HLA-DR large cells (which we here call transitional blasts) that had proliferated. The cells were then reactivated with latency-reversing agents and either luciferase or EGFP quantified. RESULTS: Inducible luciferase expression, consistent with latent infection, was observed in nonblasts and transitional blasts following stimulation with either phorbol-myristate-acetate/phytohemagglutinin (3.8 ± 1 and 2.9 ± 0.5 fold above dimethyl sulfoxide, respectively) or romidepsin (2.1 ± 0.6 and 1.8 ± 0.2 fold above dimethyl sulfoxide, respectively). Constitutive expression of luciferase was higher in transitional blasts compared with nonblasts. Using wild-type full-length EGFP reporter virus, inducible virus was observed in nonblasts but not in transitional blasts. No significant difference was observed in the response to latency-reversing agents in either nonblasts or transitional blasts. CONCLUSION: HIV latency can be established in vitro in resting T cells that have not proliferated (nonblasts) and blasts that have proliferated (transitional blasts). This model could potentially be used to assess new strategies to eliminate latency.
Authors: D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano Journal: Nat Med Date: 1999-05 Impact factor: 53.440
Authors: Julio C C Lorenzi; Yehuda Z Cohen; Lillian B Cohn; Edward F Kreider; John P Barton; Gerald H Learn; Thiago Oliveira; Christy L Lavine; Joshua A Horwitz; Allison Settler; Mila Jankovic; Michael S Seaman; Arup K Chakraborty; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig Journal: Proc Natl Acad Sci U S A Date: 2016-11-21 Impact factor: 11.205
Authors: Hao K Lu; Lachlan R Gray; Fiona Wightman; Paula Ellenberg; Gabriela Khoury; Wan-Jung Cheng; Talia M Mota; Steve Wesselingh; Paul R Gorry; Paul U Cameron; Melissa J Churchill; Sharon R Lewin Journal: PLoS One Date: 2014-11-19 Impact factor: 3.240
Authors: Nina N Hosmane; Kyungyoon J Kwon; Katherine M Bruner; Adam A Capoferri; Subul Beg; Daniel I S Rosenbloom; Brandon F Keele; Ya-Chi Ho; Janet D Siliciano; Robert F Siliciano Journal: J Exp Med Date: 2017-03-24 Impact factor: 14.307
Authors: Eun Hye Kim; Lara Manganaro; Michael Schotsaert; Brian D Brown; Lubbertus C F Mulder; Viviana Simon Journal: Cell Rep Methods Date: 2022-06-13
Authors: Elizabeth R Wonderlich; Krupa Subramanian; Bryan Cox; Ann Wiegand; Carol Lackman-Smith; Michael J Bale; Mars Stone; Rebecca Hoh; Mary F Kearney; Frank Maldarelli; Steven G Deeks; Michael P Busch; Roger G Ptak; Deanna A Kulpa Journal: PLoS Pathog Date: 2019-10-14 Impact factor: 6.823
Authors: Lesley R de Armas; Christina Gavegnano; Suresh Pallikkuth; Stefano Rinaldi; Li Pan; Emilie Battivelli; Eric Verdin; Ramzi T Younis; Rajendra Pahwa; Siôn L Williams; Raymond F Schinazi; Savita Pahwa Journal: Front Immunol Date: 2021-08-31 Impact factor: 7.561
Authors: Paula C Soto; Valeri H Terry; Mary K Lewinski; Savitha Deshmukh; Nadejda Beliakova-Bethell; Celsa A Spina Journal: PLoS One Date: 2022-07-27 Impact factor: 3.752